Literature DB >> 12175106

A multicenter cost-of-illness study on rheumatoid arthritis in Italy.

G Leardini1, F Salaffi, R Montanelli, S Gerzeli, B Canesi.   

Abstract

OBJECTIVE: Rheumatoid arthritis (RA) is a chronic and disabling disease frequently leading to physical and psychological dependence, with considerable economic consequences. The aim of our study was to perform a cost-of-illness analysis for RA according to the four different levels of functional RA severity.
METHODS: Direct costs (hospitalisations, treatments, diagnostics and the non-medical costs), indirect costs (productivity losses and informal care), and intangible costs (deterioration in the quality of life of patients, their families and friends assessed by the Medical Outcome Survey Short Form and the Stanford Health Assessment Questionnaire) were measured in 200 RA patients.
RESULTS: The social costs--direct plus indirect costs--increased as RA worsened. The direct costs increase very significantly (p < 0.0005) among the four functional classes (respectively Euro 1643.4 - 2910.2 - 4236.5 - 5696.8), likewise the indirect costs (respectively Euro 2704.9 - 9566.4 - 12183.1 - 17249.2). Moreover social costs, analysed independently from the functional classes, are significantly higher in patients with other concomitant diseases. As far as the intangible costs are concerned, for all the areas explored by the scales used, the high impact of RA on the quality of life of RA patients was markedly evident. Female gender and co-morbidity are associated with higher costs.
CONCLUSIONS: In Italy, the indirect costs account for the highest cost for management of RA patients. Considering that costs increase with RA progression, the patients who show a rapid evolution of the functional damages should be identified early based on risk indicators.

Entities:  

Mesh:

Year:  2002        PMID: 12175106

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  21 in total

1.  Characteristics of patients with rheumatoid arthritis in France: a study of 1109 patients managed by hospital based rheumatologists.

Authors:  J Sany; P Bourgeois; A Saraux; S Durieux; A Lafuma; J P Daurès; F Guillemin; J Sibilia
Journal:  Ann Rheum Dis       Date:  2004-10       Impact factor: 19.103

2.  Rheumatoid arthritis in Lebanese patients: characteristics in a tertiary referral centre in Beirut city.

Authors:  L Kalouche Khalil; R Baddoura; J Okais; H Awada
Journal:  Ann Rheum Dis       Date:  2005-09-21       Impact factor: 19.103

3.  Reliability and validity of the Italian version of the Chronic Pain Grade questionnaire in patients with musculoskeletal disorders.

Authors:  Fausto Salaffi; Andrea Stancati; Walter Grassi
Journal:  Clin Rheumatol       Date:  2006-01-19       Impact factor: 2.980

4.  Cost-effectiveness treatment with Rituximab in patients with rheumatoid arthritis in real life.

Authors:  Maurizio Benucci; Gianantonio Saviola; Paola Baiardi; Mariangela Manfredi
Journal:  Rheumatol Int       Date:  2010-05-16       Impact factor: 2.631

5.  Economic Burden of Rheumatoid Arthritis in Italy: Possible Consequences on Anti-Citrullinated Protein Antibody-Positive Patients.

Authors:  Francesco Saverio Mennini; Andrea Marcellusi; Lara Gitto; Florenzo Iannone
Journal:  Clin Drug Investig       Date:  2017-04       Impact factor: 2.859

6.  Major trends in the manifestations and treatment of rheumatoid arthritis in a multiethnic cohort in Singapore.

Authors:  Ee Tzun Koh; Justina Wei Lynn Tan; Bernard Yu-Hor Thong; Cheng Lay Teh; Tsui Yee Lian; Weng Giap Law; Arul Earnest; Kok Ooi Kong; Tang Ching Lau; Yew Kuang Cheng; Hwee Siew Howe; Wern Hui Yong; Faith Li-Ann Chia; Hiok Hee Chng; Khai Pang Leong
Journal:  Rheumatol Int       Date:  2012-12-28       Impact factor: 2.631

7.  [Productivity costs of rheumatoid arthritis in Germany. Cost composition and prediction of main cost components].

Authors:  S Merkesdal; J L Huelsemann; T Mittendorf; S Zeh; H Zeidler; J Ruof
Journal:  Z Rheumatol       Date:  2006-10       Impact factor: 1.372

8.  Burden and cost of illness in patients with juvenile idiopathic arthritis.

Authors:  K Minden; M Niewerth; J Listing; T Biedermann; M Schöntube; A Zink
Journal:  Ann Rheum Dis       Date:  2004-07       Impact factor: 19.103

9.  Determinants of direct costs in Dutch rheumatoid arthritis patients.

Authors:  S M M Verstappen; H Verkleij; J W J Bijlsma; E Buskens; A A Kruize; A H M Heurkens; M J Van Der Veen; J W G Jacobs
Journal:  Ann Rheum Dis       Date:  2004-07       Impact factor: 19.103

Review 10.  Infliximab: a pharmacoeconomic review of its use in rheumatoid arthritis.

Authors:  Katherine A Lyseng-Williamson; Rachel H Foster
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.